💊 Drugs A-Z 🧬 Targets 🛠 Tools 📚 Guides
All Drugs Drug Classes Therapeutic Areas Side Effects
Guides Glossary Timeline
Comparisons Drug Journeys Drug Families
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Sutimlimab

CHEMBL4297832 Phase 4 Approved Antibody
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
— g/mol
LogP
—
Phase
4

Sutimlimab is a humanized monoclonal IgG4 antibody that selectively targets and inhibits C1s, a serine protease in the classical complement pathway, approved for the treatment of hemolysis in adults with cold agglutinin disease (CAD). By blocking C1s-mediated cleavage of C4 and C2, it prevents classical pathway-driven complement activation on red blood cells by cold agglutinin IgM antibodies, inhibiting complement-mediated hemolysis. It is the first targeted therapy for this rare hemolytic anemia.

Therapeutic Areas

Hematology

Pharmacokinetics (PK)

Pharmacodynamics (PD)

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Frequently Asked Questions

Sutimlimab is a humanized monoclonal IgG4 antibody that selectively targets and inhibits C1s, a serine protease in the classical complement pathway, approved for the treatment of hemolysis in adults with cold agglutinin disease (CAD). By blocking C1s-mediated cleavage of C4 and C2, it prevents classical pathway-driven complement activation on red blood cells by cold agglutinin IgM antibodies, inhibiting complement-mediated hemolysis. It is the first targeted therapy for this rare hemolytic anemia.

Yes, Sutimlimab is an approved drug. It has reached clinical phase 4. It is classified as a Antibody.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL4297832. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-08-20.

Medical Disclaimer

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.